SAAKSHI Saakshi Medtech Q2 FY26 results (Jul–Sep 2025) and concall
Saakshi Medtech reported a strong H1 FY26, with revenue growing 31% YoY to Rs. 58.31 crores and EBITDA improving to 18.71%. This growth was driven by a seven-fold increase in aerospace revenue and a 40% surge in the integrated control system segment. While net profit reached Rs. 6.63 crores, the company saw a decline in cash due to ongoing CAPEX and increased working capital, alongside higher debt for facility expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 4.9%, net profit up 16.7% against the same quarter last year.
| Line item | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 69 | 61 | 61 | 44 | 48 −30% | 58 −5% |
| EBITDA | 12 | 10 | 10 | 6 | 4 −67% | 11 +10% |
| Net profit | 7 | 6 | 6 | 3 | 1 −86% | 7 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
